Myeloproliferative and thrombotic burden and treatment outcome of thrombocythemia and polycythemia patients

Figure 3 Mode of treatment in the Dutch 2008 survey of 363 myeloproliferative neoplasm (123 essential thrombocythemia, 190 polycythemia vera and 50 myelofibrosis) patients: 93% of polycythemia vera, 71% of essential thrombocythemia and 37% of myelofibrosis were on aspirin; 6% of essential thrombocythemia, 78% of polycythemia vera and 9% of myelofibrosis were treated with phlebotomy[23]. Because of symptomatic MNP disease burden 31% of ET, 29% of PV and 30% of MF were on treatment with hydroxyurea and 16% of ET, 16% of PV and 4% of MF were on treatment with pegylated interferon (Pegasys^R)[23]. ET: Essential thrombocythemia; PV: Polycythemia vera; MF: Myelofibrosis; MNP: Myeloproliferative neoplasm.